國立虎尾科技大學 |

Interleukin 12 = antitumor activity and immunotherapeutic potential in oncology /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Interleukin 12/ by Witold Lasek, Radoslaw Zagozdzon.
其他題名:	antitumor activity and immunotherapeutic potential in oncology /
作者:	Lasek, Witold.
其他作者:	Zagozdzon, Radoslaw.
出版者:	Cham :Springer International Publishing : : 2016.,
面頁冊數:	vii, 75 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Interleukin-12. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-46906-5
ISBN:	9783319469065

Interleukin 12 = antitumor activity and immunotherapeutic potential in oncology /
Lasek, Witold.

Interleukin 12antitumor activity and immunotherapeutic potential in oncology /[electronic resource] :by Witold Lasek, Radoslaw Zagozdzon. - Cham :Springer International Publishing :2016. - vii, 75 p. :ill., digital ;24 cm. - SpringerBriefs in immunology,2194-2773. - SpringerBriefs in immunology..

This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies)

ISBN: 9783319469065

Standard No.: 10.1007/978-3-319-46906-5doiSubjects--Topical Terms:

1113332
Interleukin-12.

LC Class. No.: QR185.8.I56

Dewey Class. No.: 616.079

Interleukin 12 = antitumor activity and immunotherapeutic potential in oncology /
LDR:01853nam a2200313 a 4500 001 866840
003 DE-He213
005 20160923120258.0
006 m d
007 cr nn 008maaau
008 170720s2016 gw s 0 eng d
020 $a 9783319469065 $q (electronic bk.)
020 $a 9783319469058 $q (paper)
024 7 $a 10.1007/978-3-319-46906-5 $2 doi
035 $a 978-3-319-46906-5
040 $a GP $c GP
041 0 $a eng
050 4 $a QR185.8.I56
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
082 0 4 $a 616.079 $2 23
090 $a QR185.8.I56 $b L343 2016
100 1 $a Lasek, Witold. $3 1113330
245 1 0 $a Interleukin 12 $h [electronic resource] : $b antitumor activity and immunotherapeutic potential in oncology / $c by Witold Lasek, Radoslaw Zagozdzon.
260 $a Cham : $c 2016. $b Springer International Publishing : $b Imprint: Springer,
300 $a vii, 75 p. : $b ill., digital ; $c 24 cm.
490 1 $a SpringerBriefs in immunology, $x 2194-2773
520 $a This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies)
650 0 $a Interleukin-12. $3 1113332
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Immunology. $3 592892
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Cytokines and Growth Factors. $3 787581
650 2 4 $a Oncology. $3 593951
650 2 4 $a Cell Biology. $3 593889
700 1 $a Zagozdzon, Radoslaw. $3 1113331
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a SpringerBriefs in immunology. $3 1064904
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-46906-5
950 $a Biomedical and Life Sciences (Springer-11642)